



PAHO Revolving Fund
WHO Informal Consultation to develop further
guidance on vaccine for the UNEP-INC4
Geneva, 3-4 April 2012

Monica Pereira (FCH/IM)
Specialist, Revolving Fund



1977 PAHO Directing Council Resolution CD25.R27

- ✓ **The Expanded Program on Immunization (EPI) of the Americas is created: Regional Immunization Program**
- ✓ **As part of the EPI, the Revolving Fund for Vaccine Procurement was launched in 1979 as a procurement mechanism for essential vaccines, syringes and other related supplies without interruption**



The PAHO Revolving Fund

Highlights

- More than 30 years facilitating Member States on:
 - Continuous supply of vaccines, syringes and related supplies
 - Safe and Effective products (WHO PQ)
 - Single and Lower Price
- 39 participating countries & territories

Processes

- Demand Planning
- Procurement (International Bid Solicitation & Selection)
- Shipping & Expediting
- Technical support

Key benefits

- Financial self-sustainability of the EPIs
- Elimination of vaccine preventable diseases
- Catalyst for the introduction of new vaccines (e.g Rota, Pneumo)



Immunization Program in Latin America and Caribbean - 2011

Birth cohort
American Region

15.5
millions

Birth cohort
Latin America & Caribbean

10.7
millions

Purchase of vaccines through PAHO
Revolving Fund

39
countries &
territories

8.2
millions of
births

178
millions of doses
(**79** millions of doses
contain thiomersal)



The PAHO Revolving Fund

Key Figures: 2011



39 countries & territories
Birth Cohort: 8.2 millions



1,277 orders
178 millions of doses



Purchased: US\$ 405 millions
Capital Fund: US\$ 85 millions



RF – Purchase Data

- DTP
 - Purchased since 1979
 - Slight decline with introduction of pentavalent
 - Still steady demand – 8 to 10 MM doses
 - Preference for 10-dose-vial
- Hep B
 - Introduced in 2000
 - Preference for 10-dose-vial
 - Steady demand – 15 to 18 MM doses




RF – Purchase Data

- DTP Hep B Hib (pentavalent)
 - Introduced in 2000
 - 2000-2011: 100% vial 1 dose (liq/lyo)
 - Preference for liquid presentation 95%
 - Demand: 9 MM doses + 8.8 MM ds (Brazil)
 - As of now, preference for 1-dose-vial; NO request for 10-dose-vial
- Seasonal Influenza
 - 36/39 countries have introduced
 - Mostly 10-dose-vial availability (PQ)




PAHO Revolving Fund Purchases

PAHO Thiomersal Containing vs. Non Containing Vaccines
Annual Purchased Volume (doses)



Impact of removal of thiomersal of the vaccines

Latin America and Caribbean region supplied by the PAHO Revolving Fund



Thank you

www.paho.org/revolvingfund

